RecruitingPhase 4NCT04347473

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.

Sponsor

Psoriasis Treatment Center of Central New Jersey

Enrollment

25 participants

Start Date

Apr 6, 2020

Study Type

INTERVENTIONAL

Conditions

Psoriasis

Summary

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

Male or female adult ≥ 18 years of age;
Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by
BSA 10%
PGA ≥3
PASI ≥12
Must be a candidate for phototherapy and/or systemic therapy
Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.

Exclusion Criteria4

Non-plaque forms of psoriasis
Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating
Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial.
Active or untreated latent tuberculosis (TB)

Interested in this trial?

Get notified about updates and connect with the research team.